THERAPY IV KELARE HEAVY METAL DESFERROXAMINE
Heavy Metal Toxicity refers to an overexposure to lead, mercury, arsenic, cadmium, chromium or other high density or metallic element that causes irritation or damage to the body. Heavy metals can be found naturally in the environment, in homes, or at the work place. Sudden severe exposures as well as moderate exposures over time can cause toxicity.
Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and aluminum.
Price: 775 RON - 500 mg (5 ml)
Special offer 1: 16% DISCOUNT for a package of 5 IV / IM therapies
Special offer 2: 25% DISCOUNT for 5 vitamins / minerals in one administration
Deferoxamine is used to treat acute iron poisoning, especially in small children.
This agent is also frequently used to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired.
Acquired hemochromatosis is common in patients with certain types of chronic anemia (e.g. thalassemia and myelodysplastic syndrome) who require many blood transfusions, which can greatly increase the amount of iron in the body.
Treatment with iron-chelating drugs such as deferoxamine reduces mortality in persons with sickle cell disease or β‐thalassemia who are transfusion dependent.
Administration for chronic conditions is generally accomplished by subcutaneous injection over a period of 8–12 hours each day. Administration of deferoxamine after acute intoxication may color the urine a pinkish red, a phenomenon termed "vin rosé urine". Apart from iron toxicity, deferoxamine can be used to treat aluminium toxicity (an excess of aluminium in the body) in select patients.